Doc, another question. Do you think NWBO applies for tumor agnostic with FDA or go the GBM route again? For MHRA , application consisted of a million and a half pages. I'm sure graphs and data were a majority of the application. When applying for tumor agnostic, wouldn't that require much more data on other cancers? Or do they hit the ground running and just get GBM approved and allow doctors to prescribe in combo?
It ain’t happening in 2026. 5+ years since data lock and no guidance or BLA submission tells you everything you need to know. Continue to build false expectations as you have been doing for years to recruit bag holders! ;)
I am sure LP’s financiers will appreciate that! And so will shorts.
Market Data 
Markets 
AI
